Altered expression and function of hepatic natural killer T cells in obese and diabetic KK-Ay mice

Hepatology Research

Volumn 43, Issue 3, 2013, Pages 276-288

  Yamagata, Hisafumi ^a   Ikejima, Kenichi ^a   Takeda, Kazuyoshi ^a   Aoyama, Tomonori ^a   Kon, Kazuyoshi ^a   Okumura, Ko ^a   Watanabe, Sumio ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adipokines; Innate immunity; Metabolic syndrome; Natural killer T cells; Non alcoholic steatohepatitis; Pioglitazone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA GALACTOSYLCERAMIDE; GAMMA INTERFERON; INTERLEUKIN 4; LIPOCORTIN 5; PIOGLITAZONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL FRACTIONATION; CELL FUNCTION; CELL POPULATION; CONTROLLED STUDY; DIABETIC OBESITY; DRUG EFFECT; MALE; METABOLIC SYNDROME X; MONONUCLEAR CELL; MOUSE; NATURAL KILLER T CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84874305608     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01062.x     Document Type: Article

References (38)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
2. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57.
3. Watanabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol 2008; 43: 509-18.
4. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006; 131: 934-45.
5. Li Z, Diehl AM. Innate immunity in the liver. Curr Opin Gastroenterol 2003; 19: 565-71.
6. Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 2008; 48: 670-8.
7. Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol 2009; 86: 513-28.
8. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4: 231-7.
9. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005; 23: 877-900.
10. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004; 22: 817-90.
11. Safadi R, Zigmond E, Pappo O, Shalev Z, Ilan Y. Amelioration of hepatic fibrosis via beta-glucosylceramide-mediated immune modulation is associated with altered CD8 and NKT lymphocyte distribution. Int Immunol 2007; 19: 1021-9.
12. Ginsburg I, Koren E, Horani A etal. Amelioration of hepatic fibrosis via Padma Hepaten is associated with altered natural killer T lymphocytes. Clin Exp Immunol 2009; 157: 155-64.
13. Park O, Jeong WI, Wang L etal. Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 2009; 49: 1683-94.
14. Ohkawa K, Takehara T, Tatsumi T etal. Alterations in hepatitis B virus nucleotide sequences in a chronic virus carrier from immunotolerant to immunoactive phase. Biochem Biophys Res Commun 2010; 394: 574-80.
15. Ishikawa S, Ikejima K, Yamagata H etal. CD1d-restricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice. J Hepatol 2011; 54: 1195-204.
16. Yang SQ, Lin HZ, Mandal AK, Huang J, Diehl AM. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology 2001; 34: 694-706.
17. Picard C, Lambotte L, Starkel P etal. Steatosis is not sufficient to cause an impaired regenerative response after partial hepatectomy in rats. J Hepatol 2002; 36: 645-52.
18. Iwatsuka H, Shino A, Suzuoki Z. General survey of diabetic features of yellow KK mice. Endocrinol Jpn 1970; 17: 23-35.
19. Miller MW, Duhl DM, Vrieling H etal. Cloning of the mouse agouti gene predicts a secreted protein ubiquitously expressed in mice carrying the lethal yellow mutation. Genes Dev 1993; 7: 454-67.
20. y obese mice. Hepatology 2004; 40: 177-84.
21. y mice. Hepatol Res 2006; 36: 217-28.
22. y mice are highly susceptible to oxidative hepatocellular damage induced by acetaminophen. Am J Physiol Gastrointest Liver Physiol 2010; 299: G329-37.
23. y mice. Hepatology 2009; 49: 1636-44.
24. Li Z, Soloski MJ, Diehl AM. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 2005; 42: 880-5.
25. Dumas ME, Barton RH, Toye A etal. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA 2006; 103: 12511-6.
26. DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittmann BE. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008; 83: 460-9.
27. Thurman RG II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 1998; 275: G605-11.
28. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-11.
29. Li Z, Yang S, Lin H etal. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-50.
30. Miele L, Valenza V, La Torre G etal. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-87.
31. Michalik L, Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest 2006; 116: 598-606.
32. Uchimura K, Nakamuta M, Enjoji M etal. Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. Hepatology 2001; 33: 91-9.
33. Enomoto N, Takei Y, Hirose M etal. Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. J Pharmacol Exp Ther 2003; 306: 846-54.
34. Miyahara T, Schrum L, Rippe R etal. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000; 275: 35715-22.
35. Kon K, Ikejima K, Hirose M etal. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 2002; 291: 55-61.
36. Galli A, Crabb DW, Ceni E etal. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122: 1924-40.
37. Belfort R, Harrison SA, Brown K etal. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-307.
38. Sanyal AJ, Chalasani N, Kowdley KV etal. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.